...
首页> 外文期刊>Journal of Korean medical science >Early prophylactic versus late selective use of surfactant for respiratory distress syndrome in very preterm infants: a collaborative study of 53 multi-center trials in Korea.
【24h】

Early prophylactic versus late selective use of surfactant for respiratory distress syndrome in very preterm infants: a collaborative study of 53 multi-center trials in Korea.

机译:在极早产儿中早期预防性使用和晚期选择性使用表面活性剂治疗呼吸窘迫综合征:在韩国进行的53项多中心试验的合作研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Pulmonary surfactant (PS) therapy was proven to be highly successful for the treatment of respiratory distress syndrome in premature infants. As a results, early prophylactic (EP) PS therapy has been introduced recently in Europe, the US and Korea. However, no multi-center study was compared EP and late selective (LS) PS therapies in Korea. We performed a retrospective multi-center study to compare the outcomes of EP and LS PS therapies in very preterm infants. We analyzed clinical morbidity and mortality for 1,291 infants in 2010 (LS group) and 1,249 infants in 2011 (EP group); the infants were born <30 weeks of gestation and had birth weight ≤1,250 g, and were chosen from 53 neonatal intensive care units in Korea. Compared to the LS group (22.5%), the overall mortality was better in the EP group (19.9%) and there was no increased need for retreatment.There were additional benefits in the EP group such as fewer associated complications. To the best of knowledge, our study is the first nationwide Korean study to compare the outcomes of EP and LS therapies, and it provides evidences that EP PS therapy is important in very preterm infants to improve for survival and reduce morbidities.
机译:肺表面活性剂(PS)治疗已被证明在治疗早产儿呼吸窘迫综合征方面非常成功。结果,最近在欧洲,美国和韩国引入了早期预防性(EP)PS治疗。但是,在韩国,没有多中心研究可以比较EP和晚期选择性(LS)PS疗法。我们进行了一项回顾性多中心研究,以比较极早产儿的EP和LS PS治疗的结果。我们分析了2010年(LS组)和1,2011年(EP组)的1,291例婴儿的临床发病率和死亡率;这些婴儿是从韩国的53个新生儿重症监护室中选出的,出生时小于妊娠30周,出生体重≤1,250 g。与LS组相比(22.5%),EP组的整体死亡率更高(19.9%),并且没有增加再次治疗的需要.EP组还有其他好处,例如相关并发症更少。据我们所知,我们的研究是韩国第一个比较EP和LS治疗结果的全国性研究,它提供了证据表明EP PS治疗对于非常早产的婴儿对于改善生存率和降低发病率非常重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号